Nova Bus Completes Altoona Test for 100% Battery-Electric Bus

The LFSe+, a long-range, 100 percent battery-electric bus produced by Nova Bus, a member of the Volvo Group, has completed the Federal Transit Administration’s (FTA) bus testing program at the Altoona Bus Testing Center in Pennsylvania. Through a series of tests whose outcomes are impartially examined, this stringent evaluation seeks to guarantee the safety and effectiveness of buses.

The FTA certification certifies the LFSe+’s dependability while also enabling future transit bus purchasers to participate in many US federal subsidy programs and adhere to the contractual requirements of specific Canadian clients. Nova Bus is now able to take a strategic position in the North American market thanks to the successful completion of these tests.

The Saint-Eustache plant in Quebec builds LFSe+ buses for the Canadian market, while the Plattsburgh plant in New York State builds them for the American market.

The LFSe+ is a top choice for the switch to sustainable public transportation because of its high autonomy, low maintenance costs, and complete removal of any emissions of pollutants and greenhouse gases.

Martin Larose, President of Nova Bus, said, “Attaining Altoona certification for our LFSe+ fills us with pride: it is one of the highest badges of acknowledgment of quality and longevity that our vehicles can acquire.”

Last year in October, Nova Bus unveiled its new 100% electric, long-range dual charging bus: the LFSe+, at the New York Public Transit Association conference in Albany, New York.

Recently, the Volvo Group initiated the process to establish a large-scale production plant for battery cells in Sweden to meet the growing demand for battery electric heavy-duty vehicles and machines.

Further, Volvo Energy also invested about 50 million Swedish kronor (SEK) or $4.9 million for 10 percent in the UK-based second-life battery energy storage specialist Connected Energy. Also, Volvo Car India announced that the company has set up solar power panels at community and primary health centers in the northern Indian states of Haryana and Uttar Pradesh.